Test Study by Prowess Consulting Compares the Dell PowerStore 500T Solution and IBM FlashSystem 5300 Solution
In a recent study conducted by Prowess Consulting,* the Dell™ PowerStore™ 500T solution demonstrated superior KPIs in numerous categories compared to the IBM FlashSystem® 5300 solution. These included low latency, high performance, high DRR, unified storage, and user-friendly management capabilities. The analysis goes further, describing the business value of choosing a storage solution that delivers superior results in these key categories.
'For businesses shopping for an enterprise storage solution, the Dell PowerStore 500T solution's superior performance, efficiency, usability, and cost-savings make it a compelling choice,' said Ben Fuller, Prowess Account Director.
Among its many findings, the report notes, 'the Dell PowerStore system demonstrated 0.69 milliseconds maximum average latency during snapshot creation, 52x lower than the IBM FlashSystem solution.'
To learn more about how the Dell PowerStore 500T solution compares to IBM FlashSystem 5300 solution, visit https://prowessconsulting.com/resources/240108-dell-powerstore-delivers-snapshots-performance-data-reduction-usability-technical-research-stud to view the full technical research report, research abstract, methodology, and infographic summary. To learn more about how Dell PowerStore storage solutions stack up against the competition, visit www.dell.com/en-us/dt/what-we-do/competitor-comparisons.htm.
*The analysis and reporting were done by Prowess Consulting and commissioned by Dell Technologies.
About Prowess Consulting
Prowess Consulting has been partnering with technology innovators for over 20 years, delivering trusted, high-quality solutions and strategic expertise to support their growth and operations.
Prowess Consulting is located in Bellevue, Washington, USA. For more information, please visit https://prowessconsulting.com/.
Contact Information:
Prowess Consulting
Ben Fuller
206-443-1117
Contact via Email
https://prowessconsulting.com/contact-us
Read the full story here: Test Study by Prowess Consulting Compares the Dell PowerStore 500T Solution and IBM FlashSystem 5300 Solution
Press Release Distributed by PR.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
21 minutes ago
- Washington Post
DOGE sprouts in red states, as governors embrace the cost-cutter brand and make it their own
HARRISBURG, Pa. — The brash and chaotic first days of President Donald Trump 's Department of Government Efficiency, once led by the world's richest man Elon Musk , spawned state-level DOGE mimicry as Republican governors and lawmakers aim to show they are in step with their party's leader. Governors have always made political hay out of slashing waste or taming bureaucracy, but DOGE has, in some ways, raised the stakes for them to show that they are zealously committed to cutting costs. Many drive home the point that they have always been focused on cutting government, even if they're not conducting mass layoffs .
Yahoo
33 minutes ago
- Yahoo
After Saving $1.3 Million At 35, This Doctor Wonders If It's Finally Lamborghini Time
A 35-year-old physician earning $350,000 a year has saved $1.3 million and is now wondering if it's time to stop playing it so safe and finally splurge on the dream car he's always wanted: a Lamborghini. 'I don't want to look back and think, 'I wish I had spent more and had fun when I was young,'' the doctor wrote in a popular Reddit post on r/whitecoatinvestor, a subreddit filled with financially savvy medical professionals. Don't Miss: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." $100k+ in investable assets? – no cost, no obligation. 'You want to blow 30-40% of what you made in a decade in a single afternoon?' one person asked bluntly. Another said, 'Lambo money is $1M a year or more. This is like a barista buying a Birkin bag.' Still, not everyone was against the idea. Many encouraged the physician to explore the fantasy without committing outright. One of the top responses suggested spending $1,000 or $2,000 to test drive a variety of exotic cars. 'Try them all at 150 mph and see if that's enough for you,' the commenter said. Others recommended a more practical splurge. 'A really high-end car will turn heads but it comes at like a $150K premium to something you can use that will also turn heads and drive to what is your likely capability,' one commenter said, suggesting a Porsche 911 or BMW M4 as middle-ground options. Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. Plenty of people pointed out that while $1.3 million is an impressive savings milestone, it may not justify a purchase as extravagant as a Lamborghini. One financial planner shared that a client with $2.5 million in investments still struggled with the idea of splurging. 'She ended up settling on a trip of a lifetime. We still talk about it to this day.' 'If you worked hard your entire life with the explicit purpose to buy a Lambo, then maybe you should do it,' another person said. 'However, I like cars quite a bit but would still never spend that much at that net worth.' A few were more philosophical. 'Sometimes it's not about generational wealth or even wealth beyond need. Sometimes it's just life. You really only do live once. Let no one influence your enjoyment of such.'Even those supportive of the idea urged the doctor not to buy new. 'Buy a used Huracan for $200K. The first owner took the depreciation hit. Keep it a couple years and resell for $180K,' one user advised. 'Costs you $20K in depreciation vs $100K in depreciation.' And then there were the skeptics who had been there and done that. One Porsche owner said his 911 mostly sat in the garage and was eventually sold. 'I loved my Toyota Tundra so much, the Porsche sat in the garage for six years and only got 20K miles.' Ultimately, the community's message boiled down to this: Don't let fear of missing out or burnout push you into a massive decision. Rent first, try it out, and if you love it, go for it. Just don't expect the Lambo to solve anything deeper. Read Next: Over the last five years, the price of gold has increased by approximately 83% — Investors like Bill O'Reilly and Rudy Giuliani are using this platform to UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article After Saving $1.3 Million At 35, This Doctor Wonders If It's Finally Lamborghini Time originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.
Yahoo
33 minutes ago
- Yahoo
Regeneron (REGN) Scores FDA Approval, JP Morgan Reaffirms $800 Price Target
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company secured accelerated FDA approval for Lynozyfic (linvoseltamab-gcpt) on July 2, 2025, marking a significant progress in the treatment of relapsed or refractory multiple myeloma in patients who have undergone four or more prior therapies. The approval adds depth to the company's late-stage pipeline. Moreover, it enhances the company's long-term growth trajectory in a high-need, underserved segment of the cancer market. A medical professional holding vials of biotechnology therapeutic candidate. On the other side, on July 7, JP Morgan analyst Chris Schott reiterated a Buy rating on Regeneron, while maintaining his $800 price target. Although Regeneron has faced recent headwinds, particularly around Eylea, Schott expects those pressures to ease. He points to patient affordability issues and competitive dynamics as near-term hurdles, but believes the enhanced Eylea HD formulation and expanded copay assistance programs should help stabilize sales. Offsetting some of this softness is the continued strength of Dupixent, which Schott sees as a key growth engine, especially as new indications expand its market reach. Looking ahead, Schott views the setup for Regeneron shares as compelling. With a strong balance sheet and growing contributions from Dupixent, he sees room for upside even without relying on near-term pipeline catalysts. However, potential updates, including LAG-3 data in melanoma and further clarity on Eylea, could serve as meaningful valuation drivers. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is a biotechnology company focused on discovering, developing, and distributing innovative therapies that address serious and life-threatening diseases. While we acknowledge the potential of REGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: Harvard University Stock Portfolio: Top 10 Stock Picks and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
